Insider Selling: Chimerix, Inc. (NASDAQ:CMRX) CEO Sells 7,370 Shares of Stock

Chimerix, Inc. (NASDAQ:CMRX) CEO Michael T. Andriole sold 7,370 shares of the company’s stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $4.52, for a total value of $33,312.40. Following the completion of the transaction, the chief executive officer now directly owns 609,603 shares of the company’s stock, valued at approximately $2,755,405.56. This trade represents a 1.19 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Chimerix Trading Down 3.9 %

NASDAQ:CMRX opened at $4.38 on Monday. The company has a market capitalization of $393.94 million, a P/E ratio of -4.66 and a beta of 0.35. Chimerix, Inc. has a 12 month low of $0.75 and a 12 month high of $4.65. The business’s 50-day moving average is $3.53 and its 200 day moving average is $1.83.

Institutional Investors Weigh In On Chimerix

A number of hedge funds have recently made changes to their positions in the company. Boxer Capital Management LLC purchased a new stake in shares of Chimerix in the fourth quarter worth about $7,169,000. Jane Street Group LLC purchased a new stake in Chimerix during the fourth quarter valued at approximately $62,000. Susquehanna Fundamental Investments LLC purchased a new stake in Chimerix during the fourth quarter valued at approximately $59,000. Diadema Partners LP purchased a new stake in Chimerix during the fourth quarter valued at approximately $101,000. Finally, Marshall Wace LLP raised its position in Chimerix by 1,318.5% during the fourth quarter. Marshall Wace LLP now owns 2,213,940 shares of the biopharmaceutical company’s stock valued at $7,705,000 after purchasing an additional 2,057,864 shares during the period. 45.42% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on CMRX shares. Wedbush reaffirmed an “outperform” rating and issued a $6.00 price objective on shares of Chimerix in a research note on Tuesday, December 10th. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 price objective on shares of Chimerix in a research note on Monday, December 30th.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.